drugset

drugset / Trial / NCT07057414

The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels

NCT07057414 ↗

Phase 2 Recruiting 11 enrolled Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single-center Phase IIa clinical study.

Timeline

Start: 2025-07-07
Primary completion: 2025-10-29
Completion: 2025-12-30

Publications

Background Tang X, Zhu J, Zhong Z, Luo M, Li G, Gong Z, Zhang C, Fei F, Ruan X, Zhou J, Liu G, Li G, Olson J, Ren X. Mobilization and removing of cadmium from kidney by GMDTC utilizing renal glucose reabsorption pathway. Toxicol Appl Pharmacol. 2016 Aug 15;305:143-152. doi: 10.1016/j.taap.2016.06.001. Epub 2016 Jun 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GMDTC	Unknown	2000 mg	Intravenous

Indications

No indication recorded.